October 12, 2023 11:23 AM EDT

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit

Amber Tong

Kyle LaHucik

Senior Reporter

Plus, Scholar Rock’s entry into the weight loss space, new funding for Synerkine Pharma and its lead pain program, BioLineRx’s Asia deal, Hansa Biopharma’s Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit

Amber Tong

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

FDA lifts hold on Pep­Gen's my­oton­ic dy­s­tro­phy drug; Take­da teams with can­cer non­prof­it

Senior Reporter

Sign up to read this article for free.

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit